Australia Psychedelics

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Podcast: International Cannabis And Psychedelics Co. Is Working 'Hand In Hand' With FDA To Forge New Therapy Frontiers
Australian Psychiatrists Provide First Psychedelic-Assisted Medical Treatments In 50 Years
Podcast: International Cannabis And Psychedelics Co. Is Working 'Hand In Hand' With FDA To Forge New Therapy Frontiers
Australian Psychiatrists Provide First Psychedelic-Assisted Medical Treatments In 50 Years
Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More

Australia Psychedelics Recent News

Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market
The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized Prescriber Scheme (
PharmAla's Australian JV Cortexa Orders First Commercial MDMA & Psilocybin Shipment
As Australia’s psychedelic program launches, PharmAla Biotech Holdings Inc.’s (OTC: PMBHF) new
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr.
Building Australia's Psychedelics Industry: A New Joint Venture And Why It's Important
On May 1, new partners Canadian psychedelics developer PharmAla Biotech and Australian digital healthcare business Vitura Health (formerly Cronos Australia) announced the definitive establishment of a 50-50 joint venture Cortexa. 
The Psychedelic Mushrooms Market; Between Legitimate Harvesting And Illegal Retail Sales
While psychedelics reform is clearly gaining momentum, not only in the U.S. but notably in places like Australia and less so Canada. The fact is, all compounds remain currently Schedule I drugs (or equivalents) and thus federally illegal in many countries including the U.S.
Psychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiary
Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd.
Join Renowned Psychiatrists In This Free Webinar On Psychedelic-Assisted Therapy
Australia has announced that it will become the first country in the world to reschedule the medical use of MDMA and Psilocybin, two key ingredients in psychedelic drugs.
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to deliver MDMA toward IND-enabling studies, supported by an exclusive supply deal with PharmaAla Biotech Holdings Inc.
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses
Psychedelic Research Expands In Australia With Palliative Care Partnership & New MDMA Analog Portfolio
Psyence Partners with iNGENū for Palliative Care Clinical Trial
Enveric Creates Subsidiary Down Under To Further Next-Generation Psychedelics Program
Drug development biotech company Enveric Biosciences (NASDAQ: ENVB) has created Australia-based subsidiary Enveric Therapeutics Pty. Ltd. to support the progress of its next-generation psychedelics program for anxiety disorders, EVM201, towards the clinical stage.
Incannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiary
Australia-based biopharma giant Incannex Healthcare Ltd. (NASDAQ: IXHL) has plans to commercialize its psychedelic-assisted psychotherapy business through a new subsidiary venture under the leadership of long-standing company director Peter Widdows.
Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla
The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia.
Australia's Psychedelics Therapy Provides Hope For Treatment-Resistant Mental Health Conditions
As of July 1, psilocybin and MDMA (and related substances to both) can now be prescribed by authorized psychiatrists in Australia, which has become the
Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics
Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically authorized psychiatrists to treat certain mental health conditions, such as post-traumatic stress disorder and psilocybin for treatment-resistant depression.